AI-generated analysis. Always verify with the original filing.
Cogent Biosciences, Inc. announced fourth quarter and full year 2025 financial results, reporting cash and cash equivalents of $900.8 million as of December 31, 2025, sufficient to fund operations into 2028, alongside key milestones including SUMMIT NDA submission for bezuclastinib in NonAdvSM and topline data from APEX and PEAK trials.
Event Type
Disclosure
Mandatory
Variant
8-K
and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Cogent Biosciences, Inc. on February 17, 2026, furnished he
| Metric | Value | Basis |
|---|---|---|
| Net Loss | $102.50 | |
| Net Loss | $328.90 | |
| R&D Expenses | $75.60 | |
| R&D Expenses | $269.80 | |
| G&A Expenses | $23.90 | |
| G&A Expenses | $63.60 |